Vistin Pharma ASA ( ($DE:VP4) ) has issued an update. Vistin Pharma ASA reported a revenue increase in the third quarter of 2025, driven by a 10% ...
U.S. sales of Lilly’s weight-loss treatment Zepbound nearly tripled, to $3.57 billion, in the third quarter. Meanwhile, ...
Money Talks News on MSN
The Affordable Wonder Drug That Could Change Cancer Treatment
Trump Warns of Threat to Social Security, Medicare Exclusive: Three-star general pushed out amid tensions with Hegseth GM to ...
In a large real-world Italian cohort, GLP-1 receptor agonist therapy led to measurable rates of type 2 diabetes remission, ...
A gene on the X chromosome revs up inflammation in the female brain, which may explain why rates of multiple sclerosis are ...
Researchers from Johns Hopkins Medicine and the Johns Hopkins Bloomberg School of Public Health report that an AI-powered lifestyle intervention app for prediabetes reduced the risk of diabetes ...
An experimental GLP-1/glucagon (GCP) dual receptor agonist from Eli Lilly and its Chinese partner Innovent has bested Novo Nordisk’s reigning GLP-1 semaglutide in a phase 3 study across both b | ...
People develop type 2 diabetes for a combination of reasons, like a sedentary lifestyle and an unhealthy diet, but genetics ...
Scientists at Columbia University have discovered that metformin, a common and inexpensive diabetes drug, may help treat ...
CHICAGO -- A series of large, real-world analyses supported benefit of GLP-1 receptor agonists in cardiopulmonary indications for patients with type 2 diabetes, researchers reported at the CHEST ...
A new large study suggests that a group of diabetes medications called GLP-1 receptor agonists may be better than metformin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback